July 30 (Reuters) - Competition Bureau :
* Competition Bureau requires divestitures in Teva/Ratiopharm merger
* Merger likely lead to substantial lessening of
competition in supply of certain tablets in Canada
* Merger would impact competition in acetaminophen oxycodone, morphine sulfate
tablets
* Parties must sell assets, associated licences of either
Teva or Ratiopharm related to the tablets
((Bangalore Equities Newsroom; +91 80 4135 5800; within U.S. +1 646 223 8780))
(For more news, please click here) COPYRIGHT Copyright Thomson Reuters 2010. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
* Competition Bureau requires divestitures in Teva/Ratiopharm merger
* Merger likely lead to substantial lessening of
competition in supply of certain tablets in Canada
* Merger would impact competition in acetaminophen oxycodone, morphine sulfate
tablets
* Parties must sell assets, associated licences of either
Teva or Ratiopharm related to the tablets
((Bangalore Equities Newsroom; +91 80 4135 5800; within U.S. +1 646 223 8780))
(For more news, please click here) COPYRIGHT Copyright Thomson Reuters 2010. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.